OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study

被引:4
|
作者
Clemente, Lidia [1 ]
Cennamo, Gilda [2 ]
Montorio, Daniela [1 ]
Fossataro, Federica [1 ]
Passaro, Maria Laura [1 ]
Costagliola, Ciro [1 ]
机构
[1] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, Naples, Italy
[2] Univ Naples Federico II, Publ Hlth Dept, Eye Clin, Naples, Italy
关键词
central serous chorioretinopathy; OCTA; vessel density; photodynamic therapy; eplerenone; ANGIOGRAPHY;
D O I
10.1177/11206721221131129
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate retinal and choriocapillary vessel density (VD) changes in patients with chronic central serous chorioretinopathy (CSC) treated with half-fluence verteporfin photodynamic therapy (vPDT) or eplerenone, using optical coherence tomography angiography (OCTA). Methods Patients affected by CSC and treated with vPDT and eplerenone were retrospectively studied. At baseline and 3 months after each treatment, all patients underwent a complete ophthalmological examination, including an evaluation of best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), spectral-domain optical coherence tomography (SD-OCT) and OCTA. Results Forty-eight eyes of patients with CSC were analysed. Twenty-four eyes were placed in the vPDT group, and 24 eyes formed the eplerenone group. In both groups, OCTA showed a significant improvement in the VD of deep capillary plexus (DCP) and choriocapillaris (CC) after treatments with respect to baseline (p < 0.001), whereas the VD of superficial capillary plexus (SCP) did not show significant differences (p > 0.05). The PDT group demonstrated a statistically significant increase in the VD of DCP and CC with respect to the eplerenone group (DCP p = 0.012; CC p = 0.004). A statistically significant reduction with respect to baseline in subfoveal choroidal thickness (SFCT) (p = 0.001 for vPDT group; p = 0.001 for eplerenone group) and in central foveal thickness (CFT) (p = 0.001 for vPDT group; p = 0.001 for eplerenone group) was also found. The SFCT was significantly thinnest in the PDT group with respect to the eplerenone group (p = 0.021). Conclusion OCTA allowed us to study retinal and choriocapillary vascular changes in patients with CSC treated with vPDT and eplerenone.
引用
收藏
页码:1090 / 1096
页数:7
相关论文
共 50 条
  • [1] OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study
    Uzun, Salih
    Uzun, Fatma
    Ercal, Ozlem
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024, 34 (03) : NP131 - NP131
  • [2] HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
    Smretschnig, Eva
    Ansari-Shahrezaei, Siamak
    Hagen, Stefan
    Glittenberg, Carl
    Krebs, Ilse
    Binder, Susanne
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (02): : 316 - 323
  • [3] Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study
    Manayath, George
    Verghese, Shishir
    Ranjan, Ratnesh
    Agrawal, Hitesh
    Khanna, Amishi
    Narendran, Venkatapathy
    Chhablani, Jay
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (06) : 3110 - 3116
  • [4] Reply to comment on: Optical coherence tomography angiography in central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study
    Clemente, Lidia
    Cennamo, Gilda
    Montorio, Daniela
    Fossataro, Federica
    Passaro, Maria Laura
    Costagliola, Ciro
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024, 34 (03) : NP132 - NP133
  • [5] HALF-FLUENCE PHOTODYNAMIC THERAPY IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY
    Smretschnig, Eva
    Ansari-Shahrezaei, Siamak
    Moussa, Sarah
    Glittenberg, Carl
    Krebs, Ilse
    Binder, Susanne
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (10): : 2014 - 2019
  • [6] Half-dose versus half-fluence photodynamic therapy for chronic central serous chorioretinopathy
    Matoba, Ryo
    Shiode, Yusuke
    Kawata, Tetsuhiro
    Hosokawa, Mio
    Kimura, Shuhei
    Morizane, Yuki
    Shiraga, Fumio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [7] Half-Fluence Versus Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
    Nicolo, Massimo
    Eandi, Chiara M.
    Alovisi, Camilla
    Grignolo, Federico M.
    Traverso, Carlo Enrico
    Musetti, Donatella
    Piccolino, Felice Cardillo
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 157 (05) : 1033 - 1037
  • [8] Untargeted large spot half-fluence photodynamic therapy for chronic central serous chorioretinopathy
    Bedan, Aseel Hamoud Hamoud
    Almeida, Goncalo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [9] Half-Dose Verteporfin Combined with Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
    Liu, Chun-Fu
    Chen, Lee-Jen
    Tsai, Shawn H.
    Lai, Chi-Chun
    Chan, Wei-Chun
    Wu, Wei-Chi
    Wang, Nan-Kai
    Chen, Kuan-Jen
    Hwang, Yih-Shiou
    Chen, Yen-Po
    Yeung, Ling
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2014, 30 (05) : 400 - 405
  • [10] Half-fluence Versus Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy REPLY
    Nicolo, Massimo
    Traverso, Carlo Enrico
    Musetti, Donatella
    Piccolino, Felice Cardillo
    Eandi, Chiara M.
    Alovisi, Camilla
    Grignolo, Federico M.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (01) : 205 - 206